IMRX vs LLY · $124.2M cap vs P/E 39, rev $22.97B
Immuneering Corp (IMRX) versus Eli Lilly and Company (LLY) — a side-by-side from cached financials, not a winner call.
Immuneering Corp (IMRX) is a biotechnology company listed on US.
Eli Lilly and Company (LLY) is a drug manufacturers - general company listed on NYSE. It is led by David Ricks.
Latest reported IMRX revenue for 2023-12-31 was $0. Net income was -$53.5M. Revenue was down 100.0% from 2022-12-31 to 2023-12-31. IMRX currently screens at market cap $124.2M.
Latest reported LLY revenue for 2026-06-30 was $22.97B. Net income was $7.09B. Revenue was up 16.0% from 2026-03-31 to 2026-06-30. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
IMRX currently screens at market cap $124.2M. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
Not investment advice. Open the IMRX and LLY stock pages for the full models.
Not investment advice.